European Union - English - EMA (European Medicines Agency)

pfizer ltd. - sitaxentan sodium - hypertension, pulmonary - antihypertensives, - treatment of patients with pulmonary arterial hypertension (pah) classified as who functional class iii, to improve exercise capacity. efficacy has been shown in primary pulmonary hypertension and in pulmonary hypertension associated with connective tissue disease.

Canada - English - Health Canada

pfizer canada ulc - sitaxsentan sodium - tablet - 100mg - sitaxsentan sodium 100mg - miscellaneous vasodilatating agents

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

pfizer ltd - sitaxentan sodium - tablet - 100mg